Boehringer Ingelheim Backs R&D With Big Bucks
Reports Solid Set Of Financials For 2020
Jardiance and Ofev are growing strongly but the German drugmaker is also confident its pipeline will bear fruit, boosted by a rising research budget that represents almost 23% of sales.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about a research setback in Huntington’s, big R&D investment at Boehringer, a Pfizer divestment in China, Lilly’s biomedicines plans, and the pandemic’s impact on launches and promotion.
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.